MultiCASE

MultiCASE is a long-established provider of AI-driven computational toxicology software, serving a global clientele in regulated industries. The company's core technology, rooted in research from the 1980s, automates the identification of structural features (biophores) linked to biological activity, enabling predictions for complex endpoints like genotoxicity and carcinogenicity. Its business model is centered on licensing its software platform to accelerate research, reduce animal testing, and support regulatory submissions such as ICH M7 for pharmaceutical impurities. With a focus on expanding its web-based QSAR Flex application and leveraging global distribution partners, MultiCASE is positioned at the intersection of AI/ML and life sciences software.

Fragment-based (Q)SAR modeling platform using automated identification of biophores (active substructures) and modulators to predict toxicological endpoints and metabolic fate of chemicals. Core products include CASE Ultra (toxicity), META Ultra (metabolism), and QSAR Flex (web-based weight-of-evidence tool).

Operates in a competitive niche with rivals including large commercial software suites (e.g., BIOVIA, Schrödinger), specialized non-profit consortia (e.g., Lhasa Limited), and other commercial (Q)SAR tool providers (e.g., Leadscope). MultiCASE differentiates through its long history, transparent biophore identification, and specific regulatory application expertise (e.g., ICH M7, nitrosamines).